Product Information
LYBALVI 20-10 MG TABLET is a brand product labeled by Alkermes, Inc., priced at $55.0476 per EA under NDC 65757065442. Its NADAC has been published 227 times since Apr 20, 2022.
FDA first approved this application on May 28, 2021.
Strength
20; 10 mg/1; mg/1
Manufacturer
Alkermes, Inc.NDC
65757065442
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
OLANZAPINE; SAMIDORPHAN L-MALATEApproval Type
New Drug (NDA)
FDA Application
NDA213378FDA Approved
5/28/2021
On Market Since
9/20/2021
Pharmacological Classes
Price Statistics
The NADAC for LYBALVI 20-10 MG TABLET has been published 227 times since Apr 20, 2022, and over the history we have for it it has risen 24.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $55.0476 per EA |
|---|---|
| All-time high | $55.1403 (Jun 10, 2026) |
| All-time low | $44.2732 (Apr 20, 2022) |
| 52-week high | $55.1403 |
| 52-week low | $52.3240 |
| Median price | $50.0844 |
| Average price | $49.9390 |
| Largest weekly change | +5.5% (Nov 23, 2022) |
| Weeks tracked | 227 |
| Tracking since | Apr 20, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the olanzapine and samidorphan L-malate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LYBALVI 20-10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LYBALVI 20-10 MG TABLET, manufactured by Alkermes, Inc., is $55.0476 per EA (NDC 65757065442), effective Aug 19, 2026.
How has the price of LYBALVI 20-10 MG TABLET changed over time?
Over the history we have for it, the NADAC for LYBALVI 20-10 MG TABLET has risen 24.3%. It has been tracked across 227 weekly CMS publications since Apr 20, 2022.
What are the highest and lowest recorded NADAC prices for LYBALVI 20-10 MG TABLET?
Since Apr 20, 2022, the NADAC for LYBALVI 20-10 MG TABLET has ranged from a low of $44.2732 (Apr 20, 2022) to a high of $55.1403 (Jun 10, 2026), with a median of $50.0844 per EA.
Are there cheaper alternatives to LYBALVI 20-10 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LYBALVI 20-10 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LYBALVI 20-10 MG TABLET?
LYBALVI 20-10 MG TABLET (NDC 65757065442) is labeled by Alkermes, Inc., and CMS classifies it as a brand product.